LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Search

Omnicell Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

38.59 3.43

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

36.64

Max

38.84

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-7.5M

-2M

Pardavimai

3.4M

314M

P/E

Sektoriaus vid.

912.5

121.746

Pelnas, tenkantis vienai akcijai

0.51

Pelno marža

-0.645

Darbuotojai

3,600

EBITDA

-10M

21M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+59.45% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-560M

1.7B

Ankstesnė atidarymo kaina

35.16

Ankstesnė uždarymo kaina

38.59

Naujienos nuotaikos

By Acuity

50%

50%

165 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Omnicell Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-17 23:44; UTC

Karštos akcijos

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

2026-02-17 23:20; UTC

Uždarbis

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

2026-02-17 22:57; UTC

Uždarbis

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

2026-02-17 21:59; UTC

Uždarbis

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

2026-02-17 23:54; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

2026-02-17 23:54; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-17 23:54; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-17 23:45; UTC

Rinkos pokalbiai

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

2026-02-17 23:19; UTC

Uždarbis

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

2026-02-17 23:15; UTC

Uždarbis

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

2026-02-17 22:58; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

2026-02-17 22:58; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

2026-02-17 22:57; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

2026-02-17 22:50; UTC

Įsigijimai, susijungimai, perėmimai

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

2026-02-17 22:44; UTC

Uždarbis

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

2026-02-17 22:42; UTC

Uždarbis

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

2026-02-17 22:36; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

2026-02-17 22:36; UTC

Uždarbis

Santos Final Dividend 10.3 U.S. Cents/Security

2026-02-17 22:36; UTC

Uždarbis

Santos FY Underlying Profit US$898 Million, Down 25%

2026-02-17 22:35; UTC

Uždarbis

Santos FY Revenue US$4.94 Billion, Down 8%

2026-02-17 22:35; UTC

Uždarbis

Correct: Santos FY Net Profit US$818 Million, Down 33%

2026-02-17 22:35; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

2026-02-17 22:34; UTC

Uždarbis

Santos FY Net Profit US$818 Billion, Down 33%

2026-02-17 22:02; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

2026-02-17 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

2026-02-17 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-02-17 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-17 21:49; UTC

Įsigijimai, susijungimai, perėmimai

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

2026-02-17 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

2026-02-17 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Akcijų palyginimas

Kainos pokytis

Omnicell Inc Prognozė

Kainos tikslas

By TipRanks

59.45% į viršų

12 mėnesių prognozė

Vidutinis 58.2 USD  59.45%

Aukščiausias 70 USD

Žemiausias 49 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Omnicell Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

6

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

24.23 / 30.44Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

165 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Omnicell Inc

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
help-icon Live chat